Exact Sciences Corporation (EXAS) Receives Average Recommendation of “Buy” from Analysts

Exact Sciences Corporation (NASDAQ:EXAS) has been given a consensus rating of “Buy” by the seventeen analysts that are covering the firm, MarketBeat reports. Eight analysts have rated the stock with a hold rating, eight have issued a buy rating and one has given a strong buy rating to the company. The average 12 month price target among brokers that have issued a report on the stock in the last year is $50.28.

Several research analysts have recently issued reports on EXAS shares. Canaccord Genuity upgraded shares of Exact Sciences Corporation to a “buy” rating and set a $60.00 price objective on the stock in a report on Tuesday, October 31st. Leerink Swann set a $45.00 target price on shares of Exact Sciences Corporation and gave the company a “buy” rating in a research report on Thursday, August 24th. Roth Capital lifted their target price on shares of Exact Sciences Corporation from $40.00 to $46.00 and gave the company a “buy” rating in a research report on Wednesday, July 26th. Robert W. Baird lifted their target price on shares of Exact Sciences Corporation from $49.00 to $56.00 and gave the company an “outperform” rating in a research report on Tuesday, October 31st. Finally, Vetr upgraded shares of Exact Sciences Corporation from a “sell” rating to a “hold” rating and set a $36.55 target price on the stock in a research report on Tuesday, July 25th.

Exact Sciences Corporation (NASDAQ EXAS) traded up $0.37 during trading hours on Monday, hitting $58.87. 986,100 shares of the stock traded hands, compared to its average volume of 2,533,143. Exact Sciences Corporation has a one year low of $13.05 and a one year high of $63.60. The company has a current ratio of 10.34, a quick ratio of 9.98 and a debt-to-equity ratio of 0.01.

Exact Sciences Corporation (NASDAQ:EXAS) last posted its quarterly earnings data on Monday, October 30th. The medical research company reported ($0.23) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.30) by $0.07. Exact Sciences Corporation had a negative net margin of 60.71% and a negative return on equity of 30.32%. The company had revenue of $72.60 million for the quarter, compared to the consensus estimate of $65.03 million. During the same quarter in the previous year, the firm posted ($0.36) EPS. The business’s revenue was up 158.4% compared to the same quarter last year. research analysts expect that Exact Sciences Corporation will post -1.12 earnings per share for the current year.

In related news, insider Graham Peter Lidgard sold 75,683 shares of the business’s stock in a transaction that occurred on Tuesday, September 5th. The shares were sold at an average price of $40.81, for a total transaction of $3,088,623.23. Following the completion of the sale, the insider now directly owns 308,377 shares of the company’s stock, valued at $12,584,865.37. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, CEO Kevin T. Conroy sold 137,805 shares of the business’s stock in a transaction that occurred on Thursday, November 9th. The stock was sold at an average price of $59.14, for a total transaction of $8,149,787.70. Following the sale, the chief executive officer now directly owns 967,867 shares of the company’s stock, valued at $57,239,654.38. The disclosure for this sale can be found here. Insiders have sold 415,178 shares of company stock worth $20,785,358 over the last quarter. 4.00% of the stock is owned by company insiders.

Several institutional investors and hedge funds have recently bought and sold shares of the stock. Advisor Group Inc. raised its stake in shares of Exact Sciences Corporation by 0.8% during the second quarter. Advisor Group Inc. now owns 7,866 shares of the medical research company’s stock worth $270,000 after buying an additional 65 shares during the last quarter. Ameritas Investment Partners Inc. increased its stake in Exact Sciences Corporation by 5.6% in the second quarter. Ameritas Investment Partners Inc. now owns 9,640 shares of the medical research company’s stock valued at $341,000 after purchasing an additional 511 shares in the last quarter. Northwestern Mutual Wealth Management Co. increased its stake in Exact Sciences Corporation by 17.3% in the second quarter. Northwestern Mutual Wealth Management Co. now owns 4,072 shares of the medical research company’s stock valued at $144,000 after purchasing an additional 600 shares in the last quarter. Lincoln National Corp increased its stake in Exact Sciences Corporation by 7.8% in the second quarter. Lincoln National Corp now owns 10,104 shares of the medical research company’s stock valued at $357,000 after purchasing an additional 728 shares in the last quarter. Finally, Amalgamated Bank increased its stake in Exact Sciences Corporation by 6.0% in the third quarter. Amalgamated Bank now owns 14,964 shares of the medical research company’s stock valued at $705,000 after purchasing an additional 845 shares in the last quarter. 86.04% of the stock is owned by institutional investors and hedge funds.

TRADEMARK VIOLATION NOTICE: This article was posted by Sports Perspectives and is the property of of Sports Perspectives. If you are reading this article on another site, it was illegally copied and republished in violation of U.S. and international copyright & trademark laws. The original version of this article can be viewed at https://sportsperspectives.com/2017/11/20/exact-sciences-corporation-exas-receives-average-recommendation-of-buy-from-analysts.html.

About Exact Sciences Corporation

Exact Sciences Corporation is a molecular diagnostics company. The Company focuses on the early detection and prevention of some forms of cancer. It offers a non-invasive screening test called Cologuard for the early detection of colorectal cancer and pre-cancer. Its Cologuard test is a stool-based deoxyribonucleic acid (sDNA) screening test, which utilizes a multi-target approach to detect deoxyribonucleic acid (DNA) and hemoglobin biomarkers associated with colorectal cancer and pre-cancer.

Analyst Recommendations for Exact Sciences Corporation (NASDAQ:EXAS)

Receive News & Ratings for Exact Sciences Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exact Sciences Corporation and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply